Structure Therapeutics (GPCR) Interest Expenses (2022 - 2026)
Structure Therapeutics (GPCR) posted quarterly Interest Expenses of $800000.0 for Q1 2026, up 33.33% year-over-year from $600000.0 in Q1 2025, and little changed quarter-over-quarter from $800000.0 in Q4 2025.
Structure Therapeutics (GPCR) Interest Expenses (2022 - 2026) Analysis & Trends
Structure Therapeutics' Interest Expenses history runs 5 years deep, the most recent figure standing at $800000.0 for Q1 2026.
- In Q1 2026, Interest Expenses rose 33.33% year-over-year to $800000.0; the TTM figure through Mar 2026 stood at $2.6 million (up 73.33% YoY), while the FY2025 annual figure was $253.9 million, up 272.4% from the prior year.
- Interest Expenses for Q1 2026 stood at $800000.0, roughly flat from $800000.0 in the prior quarter.
- The five-year high for Interest Expenses was $158.9 million in Q3 2023, with the low at $100000.0 in Q1 2022.
- The 5-year median for Interest Expenses is $800000.0 (2025), against an average of $39.0 million.
- The sharpest annual moves came in 2023 and 2025: Interest Expenses soared 158763.0% in 2023, then slumped 99.45% in 2025.
- Structure Therapeutics' Interest Expenses stood at $100000.0 in 2022, then jumped by 300.0% to $400000.0 in 2023, then changed by 0.0% to $400000.0 in 2024, then surged by 100.0% to $800000.0 in 2025, then changed by 0.0% to $800000.0 in 2026.
- Business Quant data shows GPCR's Interest Expenses at $800000.0 in Q1 2026, $800000.0 in Q4 2025, and $7.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Structure Therapeutics | 11.65 Bn | 11.65 Bn | - | 6.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.85 Mn |
| Jun 30, 2026 | 6.85 Mn |
| Mar 31, 2026 | 800,000.00 |
| Mar 31, 2026 | 800,000.00 |
| Dec 31, 2025 | 800,000.00 |
| Dec 31, 2025 | 800,000.00 |
| Sep 30, 2025 | 7.92 Mn |
| Sep 30, 2025 | 7.92 Mn |
| Jun 30, 2025 | 1.27 Mn |
| Jun 30, 2025 | 1.27 Mn |
| Mar 31, 2025 | 600,000.00 |
| Mar 31, 2025 | 600,000.00 |
| Dec 31, 2024 | 400,000.00 |
| Dec 31, 2024 | 400,000.00 |
| Sep 30, 2024 | 105.66 Mn |
| Sep 30, 2024 | 105.66 Mn |
| Jun 30, 2024 | 91.10 Mn |
| Jun 30, 2024 | 91.10 Mn |
| Mar 31, 2024 | 109.57 Mn |
| Mar 31, 2024 | 109.57 Mn |